| Issue |
Med Sci (Paris)
Volume 41, Number 1, Janvier 2025
Chroniques génomiques
|
|
|---|---|---|
| Page(s) | 73 - 76 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2024188 | |
| Published online | 31 janvier 2025 | |
23andMe, ou la chute d’une licorne*
The fall of an Unicom
Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la Génomique), 13007, Marseille, France
**
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
Abstract
23andMe, a company pioneering on-demand genetic profiling, has attracted much attention, millions of customers and very significant investments, as well as some lucrative collaborations with the pharmaceutical industry. Yet the company is now in deep trouble, with shares worth pennies, and may go bankrupt in the near future. This article describes the firm’s history and attempts to understand its problems.
Entreprise ayant levé au moins un milliard de dollars.
© 2025 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l’utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.